Canada Pension Plan Investment Board Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Canada Pension Plan Investment Board cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,259,598 shares of the biopharmaceutical company's stock after selling 36,886 shares during the quarter. Canada Pension Plan Investment Board owned about 0.15% of Pfizer worth $219,127,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PFE. PSI Advisors LLC grew its holdings in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after buying an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares in the last quarter. D Orazio & Associates Inc. raised its stake in shares of Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares during the period. Lipe & Dalton boosted its position in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 400 shares during the period. Finally, Oliver Luxxe Assets LLC raised its stake in shares of Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock valued at $499,000 after purchasing an additional 401 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.16 during mid-day trading on Monday, hitting $21.98. 13,970,362 shares of the stock were exchanged, compared to its average volume of 40,384,384. The company has a 50-day simple moving average of $24.88 and a 200 day simple moving average of $26.15. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $124.66 billion, a P/E ratio of 15.59, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. UBS Group cut their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and an average target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.